Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82.

View in: PubMed

subject areas

Adenocarcinoma
Administration, Oral
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
California
Chicago
Cyclophosphamide
Cystadenocarcinoma, Serous
E-Selectin
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Peritoneal Neoplasms
Prognosis
Survival Rate
Thrombospondin 1
Treatment Outcome
Vascular Endothelial Growth Factor A

authors with profiles

Gini Fleming